Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506117 | 0.90 | RIPK1 (0.41) | RIPK1P2RX7IDO1HDAC3HDAC1 | |
| SCHEMBL1506079 | 0.85 | IDO1 (0.41) | RIPK1P2RX7IDO1HDAC3HDAC1 | |
| SCHEMBL1506211 | 0.84 | IDO1 (0.40) | RIPK1P2RX7IDO1HDAC3HDAC1 | |
| SCHEMBL1506212 | 0.84 | RIPK1 (0.43) | ERBB2RIPK1P2RX7IDO1HDAC3 | |
| SCHEMBL1506304 | 0.84 | P2RX7 (0.42) | ERBB2RIPK1P2RX7IDO1HDAC3 | |
| SCHEMBL1506082 | 0.82 | P2RX7 (0.45) | ERBB2RIPK1P2RX7IDO1HDAC3 | |
| SCHEMBL10010222 | 0.81 | IDO1 (0.39) | RIPK1P2RX7IDO1HDAC3HDAC1 | |
| SCHEMBL10008870 | 0.81 | IDO1 (0.39) | RIPK1P2RX7IDO1HDAC3HDAC1 | |
| SCHEMBL10010359 | 0.81 | P2RX7 (0.40) | ERBB2RIPK1P2RX7IDO1EGFR | |
| SCHEMBL1506265 | 0.81 | IDO1 (0.40) | RIPK1P2RX7IDO1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791144-B2 | Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| EP-2491024-B1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-20 | — | — | EP | disclosed |
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | CHRM1, CHRNA1, CHRM3 | ERBB2 780/4885RIPK1 2211/4885P2RX7 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.